In gliomas, the ITGA5 transcriptional levels increased with more adverse clinicopathological characteristics, namely, greater age at diagnosis, 1p/19q non-codeletion, higher grade, wild-type isocitrate dehydrogenase (IDH) status, unmethylated MGMT status, and mesenchymal subtype (Figure 1B). This evidence concerns the gene MGMT and central nervous system cancer.